Your browser doesn't support javascript.
loading
Use of an Innovative Pharmaceutical Class Scoring Tool for Prioritized Annual Formulary Review.
Sheldon, Holly; Kostrzewa, Audrey; Werner, Shannon; Audley, Terry; Biggs, Adam; Mancuso, Taylor; Picone, Mary Frances.
Affiliation
  • Sheldon H; Froedtert & the Medical College of Wisconsin.
  • Kostrzewa A; Froedtert & the Medical College of Wisconsin.
  • Werner S; Concordia University Wisconsin.
  • Audley T; Froedtert & the Medical College of Wisconsin.
  • Biggs A; Froedtert Menomonee Falls Hospital.
  • Mancuso T; Froedtert & the Medical College of Wisconsin.
  • Picone MF; Froedtert & the Medical College of Wisconsin.
Innov Pharm ; 13(2)2022.
Article in En | MEDLINE | ID: mdl-36654702
Background: Though The Joint Commission requires health systems perform annual formulary review, guidance for how to perform this review is lacking. Published methods include comprehensive review of all pharmaceutical classes; however, this approach may not be the most efficient or effective option for a health system with a large formulary. Objective: To create a prioritization system for annual formulary review through development of a pharmaceutical class scoring tool. Methods: Drug information pharmacists developed the scoring tool, which used external and internal data to score pharmaceutical classes in 4 categories: safety, efficacy, cost, and utilization. The primary outcome, number of formulary changes resulting from pharmaceutical class review, was compared between the highest-scoring and lowest-scoring class to assess the tool's ability to prioritize high-yield class reviews. Results: The tool calculated scores for 91 pharmaceutical classes, altogether containing 962 medications. After review of the highest-scoring class, corticosteroids, 2 formulary changes were made: one dosage form was removed from formulary, and one medication was restricted to outpatient use only. Zero formulary changes resulted from review of the lowest-scoring class, pharmaceutical adjuvants. Conclusions: The tool described in this study prioritized annual formulary review efforts by identifying a pharmaceutical class with meaningful formulary optimization opportunities as the highest-scoring class, while correctly identifying a class with no optimization opportunities as the lowest-scoring class.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Innov Pharm Year: 2022 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Innov Pharm Year: 2022 Document type: Article Country of publication: